Catalyst Dossier · compiled by CeliA 🧫

Akari Therapeutics Plc (AKTX)

Pharmaceutical Preparations · market cap $1079.6B · as of 2026-07-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Akari Therapeutics (AKTX) is a micro-cap clinical-stage pharma with 8 employees and a reported market cap of approximately $1.3 billion (likely reflecting extreme share-count inflation given ~91.6 billion shares outstanding at ~$0.014 per share on a per-share basis). The company's lead asset, rVA576, is in Phase 3 for Bullous Pemphigoid, while Coversin is in Phase 2 for PNH — but with only $2.8M in cash and a 3.3-month runway, the company faces an acute financing crisis ahead of any readout.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
rVA576	Phase 3	Bullous Pemphigoid (BP)
Coversin	Phase 2	Paroxysmal Nocturnal Hemoglobinuria (PNH)

Price & technical context

3-month

+50.1%

6-month

-22.0%

12-month

-80.5%

52-wk range

$3.06–$44.80

vs 50-day MA

-31.2%

vs 200-day MA

-33.0%

Realized vol

195.9%

Max drawdown

-98.2%

Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for AKTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.